139 related articles for article (PubMed ID: 10755174)
1. Long-term effects of naltrexone on self-injurious behavior.
Sandman CA; Hetrick W; Taylor DV; Marion SD; Touchette P; Barron JL; Martinezzi V; Steinberg RM; Crinella FM
Am J Ment Retard; 2000 Mar; 105(2):103-17. PubMed ID: 10755174
[TBL] [Abstract][Full Text] [Related]
2. Naltrexone as a treatment for repetitive self-injurious behaviour:an open-label trial.
Roth AS; Ostroff RB; Hoffman RE
J Clin Psychiatry; 1996 Jun; 57(6):233-7. PubMed ID: 8666558
[TBL] [Abstract][Full Text] [Related]
3. Dissociation of POMC peptides after self-injury predicts responses to centrally acting opiate blockers.
Sandman CA; Hetrick W; Taylor DV; Chicz-DeMet A
Am J Ment Retard; 1997 Sep; 102(2):182-99. PubMed ID: 9327093
[TBL] [Abstract][Full Text] [Related]
4. Preliminary study of altered skin temperature at body sites associated with self-injurious behavior in adults who have developmental disabilities.
Symons FJ; Sutton KA; Bodfish JW
Am J Ment Retard; 2001 Jul; 106(4):336-43. PubMed ID: 11414874
[TBL] [Abstract][Full Text] [Related]
5. beta-Endorphin and ACTH are dissociated after self-injury in adults with developmental disabilities.
Sandman CA; Touchette P; Lenjavi M; Marion S; Chicz-DeMet A
Am J Ment Retard; 2003 Nov; 108(6):414-24. PubMed ID: 14561107
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.
Malekzad F; Arbabi M; Mohtasham N; Toosi P; Jaberian M; Mohajer M; Mohammadi MR; Roodsari MR; Nasiri S
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):948-50. PubMed ID: 19453814
[TBL] [Abstract][Full Text] [Related]
7. Case study: paradoxical response to naltrexone treatment of self-injurious behavior.
Benjamin S; Seek A; Tresise L; Price E; Gagnon M
J Am Acad Child Adolesc Psychiatry; 1995 Feb; 34(2):238-42. PubMed ID: 7896657
[TBL] [Abstract][Full Text] [Related]
8. Treatment of pruritus with topically applied opiate receptor antagonist.
Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M
J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241
[TBL] [Abstract][Full Text] [Related]
9. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.
Younger J; Noor N; McCue R; Mackey S
Arthritis Rheum; 2013 Feb; 65(2):529-38. PubMed ID: 23359310
[TBL] [Abstract][Full Text] [Related]
10. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study.
Willemsen-Swinkels SH; Buitelaar JK; van Engeland H
Biol Psychiatry; 1996 Jun; 39(12):1023-31. PubMed ID: 8780837
[TBL] [Abstract][Full Text] [Related]
11. Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis.
Symons FJ; Thompson A; Rodriguez MC
Ment Retard Dev Disabil Res Rev; 2004; 10(3):193-200. PubMed ID: 15611982
[TBL] [Abstract][Full Text] [Related]
12. An orally administered opiate blocker, naltrexone, attenuates self-injurious behavior.
Sandman CA; Barron JL; Colman H
Am J Ment Retard; 1990 Jul; 95(1):93-102. PubMed ID: 2167107
[TBL] [Abstract][Full Text] [Related]
13. Naltrexone effects on short-term and long-term smoking cessation.
Covey LS; Glassman AH; Stetner F
J Addict Dis; 1999; 18(1):31-40. PubMed ID: 10234561
[TBL] [Abstract][Full Text] [Related]
14. Clinical effects of naltrexone on autistic behavior.
Zingarelli G; Ellman G; Hom A; Wymore M; Heidorn S; Chicz-DeMet A
Am J Ment Retard; 1992 Jul; 97(1):57-63. PubMed ID: 1497864
[TBL] [Abstract][Full Text] [Related]
15. Opioid antagonist effects on self-injury in adults with mental retardation: response form and location as determinants of medication effects.
Thompson T; Hackenberg T; Cerutti D; Baker D; Axtell S
Am J Ment Retard; 1994 Jul; 99(1):85-102. PubMed ID: 7946257
[TBL] [Abstract][Full Text] [Related]
16. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
Hulse GK; Morris N; Arnold-Reed D; Tait RJ
Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
[TBL] [Abstract][Full Text] [Related]
17. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
[TBL] [Abstract][Full Text] [Related]
18. Naltrexone treatment of self-injurious behavior.
Godart NT; Agman G; Perdereau F; Jeammet P
J Am Acad Child Adolesc Psychiatry; 2000 Sep; 39(9):1076-8. PubMed ID: 10986803
[No Abstract] [Full Text] [Related]
19. Using analog baselines to assess the effects of naltrexone on self-injurious behavior.
Garcia D; Smith RG
Res Dev Disabil; 1999; 20(1):1-21. PubMed ID: 9987807
[TBL] [Abstract][Full Text] [Related]
20. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation.
O'Malley SS; Cooney JL; Krishnan-Sarin S; Dubin JA; McKee SA; Cooney NL; Blakeslee A; Meandzija B; Romano-Dahlgard D; Wu R; Makuch R; Jatlow P
Arch Intern Med; 2006 Mar; 166(6):667-74. PubMed ID: 16567607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
